NVO - Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data | Benzinga
Thursday, Novo Nordisk A/S (NYSE:NVO) is holding its Capital Markets Day. Its executive management and other members of senior management will provide a full review of strategy, operations, and financial targets.
During its early session, the company, at its investor event, said early trial data for its experimental obesity drug amycretin showed a higher weight loss than its Wegovy (semaglutide) treatment.
Amycretin is an oral medicine that targets the same GLP-1 hormone as other highly popular weight loss drugs like Novo’ Nordisk’s Wegovy and Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide), which regulates hunger.
In the Phase 1 trial, oral amycretin showed that ...